TB-500 50 mg (10x5mg)

TB-500 — Research Peptide (50 mg)

TB-500 is a synthetic analog of thymosin beta-4 (T?4), examined in preclinical models for roles in cytoskeletal dynamics, cell migration, angiogenesis, and wound remodeling. While it is frequently studied on its own, TB-500 is also a common research partner to BPC-157, with TB-500 emphasizing actin-related motility and re-epithelialization biology.

What It Is

• TB-500: 43-amino-acid analog of thymosin ?4, investigated for actin binding/sequestration, cell motility, microtubule/cytoskeleton remodeling, and re-epithelialization in injury models.

Proposed Mechanisms (Preclinical)

• Actin-binding motif LKKTETQ associated with cytoskeletal reorganization and cell motility.
• Wound-healing biology: re-epithelialization, angiogenesis, and granulation-tissue quality (model-dependent).
• Inflammation-pathway modulation (e.g., miR-146a/IRAK1/TRAF6 axis, exploratory).

Selected Research Highlights

• Skin/Wound Models: TB-500 (T?4) has been associated with faster re-epithelialization and contraction vs. controls in animal studies; small clinical datasets in chronic wounds have explored dose-response over multi-week protocols.
• Tendon/Ligament: TB-family peptides have been reported to support more organized collagen and improved mechanical properties post-injury.
• Muscle & Cardiac Models: Investigated for cytoskeletal remodeling and angiogenesis in skeletal-muscle injury and cardiac ischemia models.

Combining TB-500 with BPC-157 in Research

In many experimental frameworks, TB-500 is paired with BPC-157 to evaluate complementary pathways: TB-500 for actin-based cell motility and re-epithelialization; BPC-157 for endothelial integrity, angiogenic signaling, and matrix organization. Researchers may compare TB-500 alone vs. TB-500 + BPC-157 to study potential additive effects on capillary density, ECM quality, and repair-related signaling. For teams that prefer a unified preparation, MyPurePeptide also provides a BPC-157 & TB-500 Research Peptide Blend, allowing investigation of the combination in a single co-formulated vial.

Chemical Information

• TB-500 — Formula: C₂₁₂H₃₅₀N₅₆O₇₈S · MW: 4963 g/mol
• Content per vial: 50 mg TB-500 (lyophilized powder)

Specifications

• Form: Lyophilized powder (research-grade)
• Purity: ?99% (HPLC); COA per lot available
• Packaging: Sealed vials suitable for laboratory handling

Storage & Handling

• Store lyophilized vials in a cool, dry place, protected from light.
• After reconstitution: refrigerate at 2–8 °C.
• For long-term stability: store at ?20 °C; avoid repeated freeze–thaw cycles.